Efficacy and Safety of Bezafibrate Alone or in Combination with Ursodeoxycholic Acid in Primary Biliary Cholangitis: Systematic Review and Meta-Analysis-Reference-Cited by-同舟云学术

Efficacy and Safety of Bezafibrate Alone or in Combination with Ursodeoxycholic Acid in Primary Biliary Cholangitis: Systematic Review and Meta-Analysis

Published:2022-09-30 Issue:4 Volume:68 Page:1559-1573
ISSN:0163-2116
Container-title:Digestive Diseases and Sciences
language:en
Short-container-title:Dig Dis Sci

Author:

Khakoo Nidah Shabbir,Sultan Shahnaz,Reynolds John M.,Levy Cynthia^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology,Physiology

Link

https://link.springer.com/content/pdf/10.1007/s10620-022-07704-4.pdf

Reference54 articles.

1. Murillo Perez CF, Goet JC, Lammers WJ et al. Milder disease stage in patients with primary biliary cholangitis over a 44-year period: a changing natural history. Hepatology 2018;67:1920–1930. https://doi.org/10.1002/hep.29717.

2. Goel A, Kim WR. Natural history of primary biliary cholangitis in the ursodeoxycholic acid era: role of scoring systems. Clin Liver Dis 2018;22:563–578. https://doi.org/10.1016/j.cld.2018.03.007.

3. Imam MH, Lindor KD. The natural history of primary biliary cirrhosis. Semin Liver Dis 2014;34:329–333. https://doi.org/10.1055/s-0034-1383731.

4. Corpechot C, Chazouilleres O, Rousseau A et al. A placebo-controlled trial of bezafibrate in primary biliary cholangitis. N Engl J Med 2018;378:2171–2181. https://doi.org/10.1056/NEJMoa1714519.

5. Hazzan R, Tur-Kaspa R. Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid. J Clin Gastroenterol 2010;44:371–373. https://doi.org/10.1097/MCG.0b013e3181c115b3.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fabrication of osmotic pump tablets utilizing semisolid extrusion three-dimensional printing technology;International Journal of Pharmaceutics;2024-11

2. Diagnostic criteria and long-term outcomes in AIH-PBC variant syndrome under combination therapy;JHEP Reports;2024-07

3. Biliary fibrosis is an important but neglected pathological feature in hepatobiliary disorders: from molecular mechanisms to clinical implications;Medical Review;2024-07-01

4. PPAR agonists in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials;2024-05-14

5. Evaluation of potential hepatic recompensation criteria in patients with PBC and decompensated cirrhosis;Alimentary Pharmacology & Therapeutics;2024-02-26